Long-Term Experience in the Molecular Genetic Diagnosis of Friedreich Ataxia in the Russian Federation

Ismagilova, O.; Adyan, T.; Galeeva, N.; Zabnenkova, V.; Shatokhina, O.; Kazaryan, M.; Rudenskaya, G.; Dadali, E.; Saifullina, E.; Polyakov, A. Long-Term Experience in the Molecular Genetic Diagnosis of Friedreich Ataxia in the Russian Federation. Genes 2026, 17, 1169. doi:10.3390/genes17101169  

Friedreich’s ataxia in considered the most common form of autosomal recessive ataxia; however, it’s prevalence in the Russian Federation remains poorly studied. 

This paper presents the results of a long-term study on the molecular genetic causes of FRDA in Russian Federation, yielding an estimated frequency of 1:102,000 individuals for the disease associated with GAA repeat expansion.

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. today announced a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire Mantle Therapeutics Inc. and three new research collaborations supporting cerebellar-targeted development opportunities for frataxin gene therapy. Together, these transactions will simultaneously expand Lexeo's vision and capabilities beyond gene therapy, deepen the company’s focus on the multisystem burden of FA, and add multiple therapeutic approaches designed to increase or restore frataxin in the brain. These transactions are being pursued within Lexeo's existing balance sheet capacity, with cash runway guidance unchanged into 2028 and future investment decisions guided by predefined milestones to identify and prioritize the most compelling central nervous system (CNS) opportunities. 

The acquired portfolio will include: LX3010 (MTL-104), LX3030 (MTL-707), LX3050 (MTL-501) y LX3070 (MTL-801).